[1] BOOTCOV M R,BAUSKIN A R,VALENZUELA S M,et al.MIC-1, a novel macrophage inhibitory cytokine, is a divergent member of the TGF-beta superfamily[J].Proc Natl Acad Sci U S A,1997,94(21):11514-11519.
[2] BOTTNER M,SUTER-CRAZZOLARA C,SCHOBER A,et al.Expression of a novel member of the TGF-beta superfamily, growth/differentiation factor-15/macrophage-inhibiting cytokine-1(GDF-15/MIC-1)in adult rat tissues[J].Cell Tissue Res,1999,297(1):103-110.
[3] UNSICKER K,SPITTAU B,KRIEGLSTEIN K.The multiple facets of the TGF-beta family cytokine growth/differentiation factor-15/macrophage inhibitory cytokine-1[J].Cytokine Growth Factor Rev,2013,24(4):373-384.
[4] BEREZIN A E.Diabetes mellitus related biomarker:the predictive role of growth-differentiation factor-15[J].Diabetes Metab Syndr,2016,10(1 Suppl 1):S154-157.
[5] ADELA R,BANERJEE S K.GDF-15 as a Target and biomarker for diabetes and cardiovascular diseases:a translational prospective[J].J Diabetes Res,2015,2015:490842.
[6] WOLLERT K C,KEMPF T,WALLENTIN L.Growth differentiation factor 15 as a biomarker in cardiovascular disease[J].Clin Chem,2017,63(1):140-151.
[7] OLECHNICKI M,KASPRZAK K,GOCH A.Growth differentiation factor 15-a new marker in heart diseases[J].Pol Merkur Lekarski,2010,28(168):470-472.
[8] EMMERSON P J,WANG F,DU Y,et al.The metabolic effects of GDF15 are mediated by the orphan receptor GFRAL[J].Nat Med,2017,23(10):1215-1219.
[9] GAGGIN H K,JANUZZI J LJr.Biomarkers and diagnostics in heart failure[J].Biochim Biophys Acta,2013,1832(12):2442-2450.
[10] RICHTER B,KOLLER L,HOHENSINNER P J,et al.A multi-biomarker risk score improves prediction of long-term mortality in patients with advanced heart failure[J].Int J Cardiol,2013,168(2):1251-1257.
[11] ZHANG Y,LIANG X,LIAO S,et al.Potent paracrine effects of human induced pluripotent stem cell-derived mesenchymal stem cells attenuate doxorubicin-induced cardiomyopathy[J].Sci Rep,2015,5:11235.
[12] ZHANG Y,MOSZCZYNSKI L A,LIU Q,et al.Over-expression of growth differentiation factor 15(GDF15)preventing cold ischemia reperfusion (I/R)injury in heart transplantation through Foxo3a signaling[J].Oncotarget,2017,8(22):36531-36544.
[13] SUN R R,LU L,LIU M,et al.Biomarkers and heart disease[J].Eur Rev Med Pharmacol Sci,2014,18(19):2927-2935.
[14] HEGER J,SCHIEGNITZ E,von WALDTHAUSEN D,et al.Growth differentiation factor 15 acts anti-apoptotic and pro-hypertrophic in adult cardiomyocytes[J].J Cell Physiol,2010,224(1):120-126.
[15] XU J,KIMBALL T R,LORENZ J N,et al.GDF15/MIC-1 functions as a protective and antihypertrophic factor released from the myocardium in association with SMAD protein activation[J].Circ Res,2006,98(3):342-350.
[16] ZANKOV D P,SATO A,SHIMIZU A,et al.Differential effects of myocardial afadin on pressure overload-induced compensated cardiac hypertrophy[J].Circ J,2017,81(12):1862-1870.
[17] WANG F F,CHEN B X,YU H Y,et al.Correlation between growth differentiation factor-15 and collagen metabolism indicators in patients with myocardial infarction and heart failure[J].J Geriatr Cardiol,2016,13(1):88-93.
[18] BROWN D A,BREIT S N,BURING J,et al.Concentration in plasma of macrophage inhibitory cytokine-1 and risk of cardiovascular events in women:a nested case-control study[J].Lancet,2002,359(9324):2159-2163.
[19] IZUMIYA Y,HANATANI S,KIMURA Y,et al.Growth differentiation factor-15 is a useful prognostic marker in patients with heart failure with preserved ejection fraction[J].Can J Cardiol,2014,30(3):338-344.
[20] ZHU Z D,SUN T.Association between growth differentiation factor-15 and chronic heart failure in coronary atherosclerosis patients[J].Genet Mol Res,2015,14(1):2225-2233.
[21] EINDHOVEN J A,van den BOSCH A E,OEMRAWSINGH R M,et al.Release of growth-differentiation factor 15 and associations with cardiac function in adult patients with congenital heart disease[J].Int J Cardiol,2016,202:246-251.
[22] XANTHAKIS V,LARSON M G,WOLLERT K C,et al.Association of novel biomarkers of cardiovascular stress with left ventricular hypertrophy and dysfunction:implications for screening[J].J Am Heart Assoc,2013,2(6):e000399.
[23] STENEMO M,NOWAK C,BYBERG L,et al.Circulating proteins as predictors of incident heart failure in the elderly[J].Eur J Heart Fail,2018,20(1):55-62.
[24] SINNING C,KEMPF T,SCHWARZL M,et al.Biomarkers for characterization of heart failure-distinction of heart failure with preserved and reduced ejection fraction[J].Int J Cardiol,2017,227:272-277.
[25] MELUZIN J,TOMANDL J.Can biomarkers help to diagnose early heart failure with preserved ejection fraction?[J].Dis Markers,2015,2015:426045.
[26] NOLTE K,GABRIEL F,STAHRENBERG R,et al.GDF-15, MRproADM, CTproET1, and CTproAVP in patients with asymptomatic diastolic dysfunction[J].Dtsch Med Wochenschr,2015,140(13):e120-128.
[27] CHAN M M,SANTHANAKRISHNAN R,CHONG J P,et al.Growth differentiation factor 15 in heart failure with preserved vs.reduced ejection fraction[J].Eur J Heart Fail,2016,18(1):81-88.
[28] HAUSER J A,DEMYANETS S,RUSAI K,et al.Diagnostic performance and reference values of novel biomarkers of paediatric heart failure[J].Heart,2016,102(20):1633-1639.
[29] STAHRENBERG R,EDELMANN F,MENDE M,et al.The novel biomarker growth differentiation factor 15 in heart failure with normal ejection fraction[J].Eur J Heart Fail,2010,12(12):1309-1316.
[30] SANTHANAKRISHNAN R,CHONG J P,NG T P,et al.Growth differentiation factor 15, ST2, high-sensitivity troponin T, and N-terminal pro brain natriuretic peptide in heart failure with preserved vs.reduced ejection fraction[J].Eur J Heart Fail,2012,14(12):1338-1347.
[31] SINNING C,OJEDA F,WILD P S,et al.Midregional proadrenomedullin and growth differentiation factor-15 are not influenced by obesity in heart failure patients[J].Clin Res Cardiol,2017,106(6):401-410.
[32] BAESSLER A,STRACK C,ROUSSEVA E,et al.Growth-differentiation factor-15 improves reclassification for the diagnosis of heart failure with normal ejection fraction in morbid obesity[J].Eur J Heart Fail,2012,14(11):1240-1248.
[33] ZENG X,LI L,WEN H,et al.Growth-differentiation factor 15 as a predictor of mortality in patients with heart failure:a meta-analysis[J].J Cardiovasc Med (Hagerstown),2017,18(2):53-59.
[34] SHARMA A,STEVENS S R,LUCAS J,et al.Utility of growth differentiation factor-15, a marker of oxidative stress and inflammation, in chronic heart failure:insights from the HF-ACTION Study[J].JACC Heart Fail,2017,5(10):724-734.
[35] MEREDITH A J,DAI D L Y,CHEN V,et al.Circulating biomarker responses to medical management vs. mechanical circulatory support in severe inotrope-dependent acute heart failure[J].ESC Heart Fail,2016,3(2):86-96.
[36] KOPYTSYA M,VYSHNEVSKA I,PROTSENKO O,et al.Growth differentiation factor 15 as a prognostic marker of chronic heart failure progression in long-term follow-up after acute coronary syndrome[J].Georgian Med News,2017(271):61-66.
[37] WANG H,CHEN Q,LI Y,et al.Prognostic value of growth differentiation factor-15 in Chinese patients with heart failure:A prospective observational study[J].Cardiol J,2018,25(2):245-253.
[38] GEORGE M,JENA A,SRIVATSAN V,et al.GDF 15:a novel biomarker in the offing for heart failure[J].Curr Cardiol Rev,2016,12(1):37-46.
[39] WALLENTIN L,HIJAZI Z,ANDERSSON U,et al.Growth differentiation factor 15, a marker of oxidative stress and inflammation, for risk assessment in patients with atrial fibrillation:insights from the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE)trial[J].Circulation,2014,130(21):1847-1858.
[40] STOJKOVIC S,KAIDER A,KOLLER L,et al.GDF-15 is a better complimentary marker for risk stratification of arrhythmic death in non-ischaemic, dilated cardiomyopathy than soluble ST2[J].J Cell Mol Med,2018,22(4):2422-2429.
[41] HAGE C,MICHAELSSON E,LINDE C,et al.Inflammatory biomarkers predict heart failure severity and prognosis in patients with heart failure with preserved ejection fraction:a holistic proteomic approach[J].Circ Cardiovasc Genet,2017,10(1):e001633.
[42] MEIJERS W C,van der VELDE A R,MULLER KOBOLD A C,et al.Variability of biomarkers in patients with chronic heart failure and healthy controls[J].Eur J Heart Fail,2017,19(3):357-365.
[43] LOK D J,KLIP I T,LOK S I,et al.Incremental prognostic power of novel biomarkers (growth-differentiation factor-15, high-sensitivity C-reactive protein, galectin-3, and high-sensitivity troponin-T)in patients with advanced chronic heart failure[J].Am J Cardiol,2013,112(6):831-837.
[44] JIRAK P,FEJZIC D,PAAR V,et al.Influences of Ivabradine treatment on serum levels of cardiac biomarkers sST2, GDF-15, suPAR and H-FABP in patients with chronic heart failure[J].Acta Pharmacol Sin,2017,[2017-12-14], doi:10.1038/aps 2017.167 |
